KEI Comments Regarding NIH Exclusive License to Paz Pharmaceuticals for Cancer Treatment

On July 7, 2020, Knowledge Ecology International (KEI) submitted comments to the Federal Register notice for the National Institutes of Health’s (NIH) “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Fenoterol and Certain Fenoterol Analogues for the… Continue Reading

Joint Comments Regarding NIH Exclusive License to Ziopharm Oncology for Cell Therapy

(Update: The NIH provided a response to our comments on July 16, 2020) On July 6, 2020, Knowledge Ecology International and the Union for Affordable Cancer Treatment submitted joint comments regarding the National Institutes of Health’s (NIH) proposed exclusive license… Continue Reading

KEI and UACT Comments Regarding NIH Exclusive License to Retargeted Therapeutics for Cancer Treatment

Update: The NIH sent a response to our comments, available here. The response fails to address the glaring lack of information available regarding Retargeted Therapeutics. On June 8, 2020, Knowledge Ecology International and the Union for Affordable Cancer Treatment (UACT)… Continue Reading

KEI Comments on NIH Exclusive License to Kriya Therapeutics for Diabetes and Obesity Treatment

On Tuesday April 28, 2020, KEI submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: AAV Mediated Exendin-4 Gene Transfer to Salivary Glands To Protect Subjects From Diabetes or Obesity” (85… Continue Reading

KEI Comments Regarding NIH Exclusive License for Treatment of Cancer to NeoImmune Tech

On Friday April 17, 2020, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: The Development of Bispecific Antibodies Targeting Glypican 1 (GPC1) for the Treatment of… Continue Reading

KEI Comments Regarding NIH Exclusive License for Adoptive Cell Therapy to Lyell Immunopharma

On Friday April 17, 2020, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Methods and Compositions for Adoptive Cell Therapy” to Lyell Immunopharma, Inc. (85 FR… Continue Reading

KEI Comments Regarding NIH Exclusive License to TeraImmune for T Cell Therapy

(UPDATE: The NIH provided a response to our comments on February 25, 2020) On February 3, 2020, Knowledge Ecology International (KEI) submitted comments to the “Prospective Grant of Exclusive Patent License: Development of Regulatory T-Cell Therapies for the Treatment of… Continue Reading

KEI Comments Regarding NIH Exclusive License on Gene Therapy to Treat Ocular Disease

On Friday January 10, 2020, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Gene Therapy for Ocular Disease” to OcQuila Therapeutics, Ltd. (84 FR 65169). The… Continue Reading

KEI, UACT, Public Citizen, SSW, LWC Health Appeal NIH Grant of Exclusive License on Gene Therapy for Cancer to Intima Biosciences

On October 26, 2019, Knowledge Ecology International (KEI), Union for Affordable Cancer Treatment (UACT), Public Citizen, Social Security Works (SSW), LWC Health, Ruth Lopert, Manon Ress, and Terry Love filed an administrative appeal with the National Institutes of Health (NIH).… Continue Reading

KEI and UACT Comments Regarding NIH Exclusive License on GPC3-Expressing Cancer Treatment

On Tuesday November 12, 2019, KEI and the Union for Affordable Cancer Treatment (UACT) filed comments on the National Institutes of Health’s (NIH) “Prospective Grant of an Exclusive Patent License: The Development of an Anti-GPC3 Radionuclide Immunoconjugate for the Treatment… Continue Reading